Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

Jeffrey D. Browning, Lidia S. Szczepaniak, Robert L. Dobbins et al. · Hepatology · 2004 · 3.6K citations

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.2K citations · Full text

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

Christopher D. Williams, Joel Z. Stengel, Michael Asike et al. · Gastroenterology · 2010 · 2.2K citations · Full text

Metabolic Associated Steatohepatitis, Hepatology, Metabolic Associated Steatotic Liver Disease +9

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

Hepatology, Medicine, Liver Physiology +7

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2K citations · Full text

Placebo-controlled Phase 2, Liraglutide Safety, Hepatology +5